Policy in Focus: Unpacking GLOBE, GUARD, and TrumpRx with Alice Valder Curran

Slowly but surely – and just in time for the State of the Union – the full picture of the Trump Administration’s Most-Favoured Nations drug pricing policy is coming into focus. At the end of last year, CMS published the draft guidance for its GLOBE and GUARD pricing models, which establish MFN pricing in Medicare Part B and Part D, respectively. And earlier this month TrumpRx – the government’s promised patient-facing discount portal – finally went live.

On today’s podcast, Jonah Comstock is joined by Alice Valder Curran, a partner at Hogan Lovells and a healthcare policy expert, to break down what we know and what we still don’t know about each of these developments.

Among other things, Valder Curran breaks down how the two CMS pilot programmes will work, what statutory authority CMS is leaning on (and whether that authority is likely to be challenged), and how the industry is responding. Comstock and Valder Curran also discuss TrumpRx and how impactful it’s shaping up to be, at least based on what’s been revealed so far. And how do those negotiated MFN deals fit in to all this?

We can’t give you the answers to all your questions about MFN – too much is still up in the air. But this podcast will at least give you an idea of what those open questions are and how they’re likely to play out.

You can listen to episode 246 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.